Cellectar Biosciences
CLRB
44 hedge funds and large institutions have $24.2M invested in Cellectar Biosciences in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 11 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
13% more funds holding
Funds holding: 39 → 44 (+5)
0.03% less ownership
Funds ownership: 0.13% → 0.1% (-0.03%)
34% less capital invested
Capital invested by funds: $36.9M → $24.2M (-$12.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$1.28M |
| 2 |
Renaissance Technologies
New York
|
+$1.23M |
| 3 |
Two Sigma Investments
New York
|
+$1.22M |
| 4 |
Millennium Management
New York
|
+$452K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.31M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.93M |
| 3 |
ACM
Altium Capital Management
New York
|
-$1.77M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.63M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$1.37M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citadel Advisors
Miami,
Florida
| – | -$71K | -114 | Closed |
|
|
LC
52
Lindbrook Capital
Calabasas,
California
| – | -$21K | -33 | Closed |
|
|
MWM
53
Modera Wealth Management
Westwood,
New Jersey
| – | -$21K | -33 | Closed |
|
|
SIAG
54
Safeguard Investment Advisory Group
Corona,
California
| – | -$2K | -3 | Closed |
|
CLRB Hedge Fund Activity: Q1 2021 in Review
44 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2021, worth a combined $24.2M — down 34% from $36.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CLRB positions and 11 closed out — a net gain of 5 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $1.28M. The largest seller was Silverarc Capital Management, cutting an estimated $2.31M.
- 44 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2021, up from 39 in Q4 2020.
- Funds reported $24.2M of Cellectar Biosciences stock for Q1 2021, down 34% quarter-over-quarter.
- 16 funds opened new Cellectar Biosciences positions in Q1 2021 and 11 closed out, a net change of +5 holders.
- The largest Cellectar Biosciences buyer in Q1 2021 was Two Sigma Advisers, an estimated $1.28M added.
- The largest Cellectar Biosciences seller in Q1 2021 was Silverarc Capital Management, an estimated $2.31M sold.
Based on aggregated 13F filings for Q1 2021.